In March 1999, ACAM presidents L. Terry Chappell and Ted Rozema shilled for chelation at a hearing of the House Committee on Government Reform, chaired by a powerful "health freedom" ally and veteran ...

Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients ...

CHELATION THERAPY HAS been around for decades as a treatment for toxic metal poisoning. But, there have also been claims that the therapy could help several other conditions. Experts aren't so sure.

Each month, Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Chelation therapy, a type ...

Please provide your email address to receive an email when new articles are posted on . Chelation therapy involves IV infusions of an agent that binds to metals such as lead and cadmium and is ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium-based chelation, a therapy that draws lead and other toxic metals linked to increased risk of ...

You probably won't find chelation therapy being offered at your average doctor's office. But it's a big part of alternative medical practices. It's most commonly used to treat heavy-metal poisoning. A ...

But, under anti-vaccine Health Secretary Robert F. Kennedy Jr.—who has numerous ties to the wellness industry—that FDA ...

When determining the types of patients to be recruited for the trial, there was concern that the benefits of chelation might not be easily discerned if the participants were too healthy; patients who ...

The National Institutes of Health (NIH) Trial to Assess Chelation Therapy (TACT) was begun in 2003 and is expected to be completed in 2009. It is a trial of office-based, intravenous disodium ethylene ...